Aryeh Jason, a director at Ligand Pharmaceuticals Inc., has filed a notice to sell 282 shares of the company. This transaction, valued at approximately $90,225, was reported in a recent SEC filing.

The filing, dated November 4, 2026, indicates that Jason acquired these shares through a secondary market purchase on May 14, 2019. The shares are classified as Class B common stock of Ligand Pharmaceuticals, which operates in the pharmaceutical preparations sector.

Background

Ligand Pharmaceuticals Inc. is a company incorporated in Delaware, primarily engaged in the development of pharmaceutical preparations. The company is listed on the Nasdaq under the SEC file number 001-33093. Its business address is located at 3911 Sorrento Valley Blvd, Suite 110, San Diego, CA 92121.

What the Filing Says

The SEC filing reveals that Jason sold the shares through Wells Fargo Clearing Services. The approximate sale date was noted as November 4, 2026, with a total of 282 units sold from an outstanding total of 20,002,986 units.

Impact

This sale may affect investor sentiment regarding Ligand Pharmaceuticals, especially as Jason has been actively trading shares in recent months. In the past three months alone, he sold a total of 2,111 shares, generating gross proceeds of over $600,000. Such transactions can signal to investors about the company's performance and future outlook.

What's Next

The filing does not say what happens next.